Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 16;388(7):665-667.
doi: 10.1056/NEJMc2214114. Epub 2023 Jan 18.

Protection against Reinfection with the Omicron BA.2.75 Subvariant

Hiam Chemaitelly  1 , Patrick Tang  2 , Peter Coyle  3 , Hadi M Yassine  4 , Hebah A Al-Khatib  4 , Maria K Smatti  4 , Mohammad R Hasan  2 , Houssein H Ayoub  4 , Heba N Altarawneh  5 , Zaina Al-Kanaani  3 , Einas Al-Kuwari  3 , Andrew Jeremijenko  3 , Anvar H Kaleeckal  3 , Ali N Latif  3 , Riyazuddin M Shaik  3 , Hanan F Abdul-Rahim  4 , Gheyath K Nasrallah  4 , Mohamed G Al-Kuwari  6 , Adeel A Butt  3 , Hamad E Al-Romaihi  7 , Mohamed H Al-Thani  7 , Abdullatif Al-Khal  3 , Roberto Bertollini  7 , Laith J Abu-Raddad  8 ; National Study Group for COVID-19 Epidemiology
Affiliations

Protection against Reinfection with the Omicron BA.2.75 Subvariant

Hiam Chemaitelly et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Effectiveness of Previous SARS-CoV-2 Infection in Preventing Reinfection, Irrespective of the Presence of Symptoms, with an Omicron BA.2.75 Subvariant.
The study was conducted in Qatar between September 10, 2022, and October 18, 2022. Previous infections were classified as pre-omicron infections if the positive test result was obtained before the onset of the omicron wave on December 19, 2021, and as omicron infections (BA.1 or BA.2 infections or BA.4 or BA.5 infections) if the positive test result was obtained on or after that date. Case participants (persons with positive severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] tests) and controls (persons with negative SARS-CoV-2 tests) were matched exactly according to sex, 10-year age group, nationality, number of coexisting medical conditions, number of vaccine doses that had been received by the time of the SARS-CoV-2 test, calendar week of testing, method of testing, and reason for testing. 𝙸 bars indicate 95% confidence intervals.
See this image and copyright information in PMC

References

    1. Ayoub HH, Tomy M, Chemaitelly H, et al. Estimating protection afforded by prior infection in preventing reinfection: applying the test-negative study design. January 3, 2022. (https://www.medrxiv.org/content/10.1101/2022.01.02.22268622v1). preprint. - PMC - PubMed
    1. Altarawneh HN, Chemaitelly H, Ayoub HH, et al. Protective effect of previous SARS-CoV-2 infection against omicron BA.4 and BA.5 subvariants. N Engl J Med 2022;387:1620-1622. - PMC - PubMed
    1. Chemaitelly H, Ayoub HH, Tang P, et al. Immune imprinting and protection against repeat reinfection with SARS-CoV-2. N Engl J Med 2022;387:1716-1718. - PMC - PubMed
    1. Chemaitelly H, Ayoub HH, Tang P, et al. COVID-19 primary series and booster vaccination and immune imprinting. November 1, 2022. (https://www.medrxiv.org/content/10.1101/2022.10.31.22281756v1). preprint.
    1. Chemaitelly H, Nagelkerke N, Ayoub HH, et al. Duration of immune protection of SARS-CoV-2 natural infection against reinfection. J Travel Med 2022;29:taac109-taac109. - PMC - PubMed

Supplementary concepts